Dario unveils groundbreaking glp-1 and ai-personalization digital health findings

Dario's new research shows sustained outcomes post-glp-1 for platform users and 89% accuracy in innovative ai blood glucose prediction; the company is actively working to leverage these findings in commercial discussions new york , june 24, 2025 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th annual american diabetes association ("ada") scientific sessions in chicago. the research, which represents dario's 25th published study at the ada's scientific sessions over the last decade, includes groundbreaking findings in sustaining glp-1 weight loss and artificial intelligence ("ai")-powered personalization that highlight the company's platform's critical contribution in the digital health market.
DRIO Ratings Summary
DRIO Quant Ranking